AI-generated analysis. Always verify with the original filing.
AngioDynamics reported fiscal Q3 2026 net sales of $78.4 million (+8.9% YoY) and raised its full-year FY2026 guidance for net sales and Adjusted EBITDA, driven by 19.0% growth in its Med Tech segment.
AngioDynamics delivered a strong fiscal third quarter, characterized by sustained double-digit growth in its Med Tech segment which offset softer performance in the Med Device segment. Total net sales rose 8.9% year-over-year to $78.4 million, primarily driven by the Med Tech segment's 19.0% growth to $37.3 million. Key growth drivers included the Auryon peripheral atherectomy platform (+17.9%), the Mechanical Thrombectomy portfolio (+17.9%), and the NanoKnife platform (+21.0%). Management highlighted that commercial adoption of the mechanical thrombectomy portfolio is building and that NanoKnife adoption is accelerating following the recent CPT 1 code for prostate procedures.
Profitability metrics showed mixed results. GAAP gross margin contracted 110 basis points to 52.9%, attributed to tariff impacts, inflation, and manufacturing transition costs. The company recorded $1.3 million in tariff-related expenses during the quarter. Despite margin pressure, operational discipline led to an improved Adjusted EBITDA of $1.8 million, up from $1.3 million in the prior-year period. The GAAP net loss was $8.1 million, or $0.19 per share.
Reflecting confidence in the business trajectory, management raised full-year FY2026 guidance for the third consecutive quarter. Net sales guidance was increased to a range of $313.5 million to $315.5 million, and Adjusted EBITDA guidance was raised to $10.0 million to $12.0 million. The company maintained its gross margin outlook and expects a $4.0 to $6.0 million impact from tariffs for the full fiscal year. While the company remains debt-free with $37.8 million in cash, it noted that proactive inventory building to address vendor sterilization shutdowns may result in slightly negative cash flow for the fiscal year.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan
of this Form 8-K (including Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities un
Financial Statements and Exhibits. (d) Exhibits . Exhibit No.: 99.1 | Description: Press Release, dated April 2, 2026. Exhibit No.: 99.2 | Description: Presenta
| Metric | Value | Basis |
|---|---|---|
| Net Sales | $78.40 | |
| Med Tech Net Sales | $37.30 | |
| Med Device Net Sales | $41.10 | |
| Gross Margin | 52.9% | GAAP |
| Net Loss | $8.10 | GAAP |
| Loss Per Share | $-0.19 | GAAP |
| Loss Per Share | $-0.07 | Non-GAAP |
| Adjusted EBITDA | $1.80 | Non-GAAP |